Jim Cramer Says He Would Prefer Eli Lilly (LLY) Over Regeneron Even at $900

Yahoo Finance13:19 ET

Eli Lilly's Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients

Benzinga11:28 ET

'Eli Lilly to Sell Zepbound Through Telehealth Company Ro' - Barron's

Benzinga11:25 ET

Eli Lilly Ties Up With Ro to Improve Availability of Weight-Loss Drug Zepbound in Vials

MT Newswires11:10 ET

Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock

Kevin TraversDec 11 10:47 ET

BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $997

Moomoo NewsDec 11 10:32 ET · Ratings